News
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after the stock rebounded ...
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...
Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...
Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Invest in Now. On August 7, Eli Lilly and Company (NYSE:LLY) ...
9h
Fashion Glamp on MSNA Pivotal Advance in Obesity Treatment: Eli Lilly's Oral Pill Shows Significant Weight Loss in Landmark TrialA transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Topline data were announced from a phase 3 trial evaluating orforglipron in adults with obesity or overweight with weight-related comorbidities.
A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.
On August 9, Fundstrat’s Tom Lee appeared on CNBC to discuss the current state of the market and the potential for further ...
Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results